Bernstein Downgrades Novo Nordisk (NVO) to Underperform
More News related to NVO
- Merrill Lynch Upgrades Novo Nordisk (NVO) to Neutral
- VLST Corporation and Novo Nordisk Announce Collaboration Agreement to Develop Therapeutics for Autoimmune and Inflammatory Disorders
- Matrix Lighthouse Rating Changes 11/28
- Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of Insulin Analogues
- Study Finds Cost of Diabetes in the United States Exceeds $217 Billion
More News related to Downgrades
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Sanford Bernstein downgrades Novo Nordisk (NYSE: NVO) from Market Perform to Underperform.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
Related Categories
DowngradesStocks Mentioned
-0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
